Allo-HSCT as First-line Consolidation in High-risk PTCL

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Sep 13, 2018

Keywords

ClinConnect Summary

After primary diagnosis eligible patients receive 2 to 3 courses of CHOEP-21 with formal restaging after course 2. Patients with CR, PR or no change proceed to allo-HSCT. Donor selection: Matched sibling donor(MSD) is the first choice. An unrelated donor or haploidentical family donor search is performed in patients without sibling donor. The primary end point was 1 year progression-free survival. The secondary end points were complete commission rate, transplant-related mortality, overall survival, relapse rate and graft-versus-host disease (GVHD) . Following time is 2 years

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary diagnosis of mature T-cell lymphoma, stage 2-4, or stage 1 with aa IPI\>=0
• • age \<= 60 years
• • KPS\>=70
• Exclusion Criteria:
• • stage I with aaIPI 0, ALCL ALK positive, T-lymphoblastic lymphoma, cutaneous T-cell lymphoma
• • HIV positivity
• • major organ dysfunction
• • pregnancy
• • patient unable to give informed consent